Afzal Nadeem1, Khursheed Javaid2, Waqas Sami3, Abu Zafar4, Shah Jahan2, Shakeela Zaman5, Ah Nagi6. 1. Department of lmmunology, University of Health Sciences, Lahore, Pakistan. immunology@uhs.edu.pk 2. Department of lmmunology, University of Health Sciences, Lahore, Pakistan. 3. Departments of Biostatics, University of Health Sciences, Lahore, Pakistan. 4. Amin Hayal Memorial Diabetic Centre, Lahore, Pakistan. 5. Children Hospital & Institute of Child Health, Lahore, Pakistan. 6. Department of Pathology, University of Health Sciences, Lahore, Pakistan.
Abstract
BACKGROUND: Diabetes mellitus (DM) is a health concern because it leads to complications such as retinopathy. Pakistan has 6.9 million DM affected people that will double by 2025. A study was designed to determine the level of IL-17 in the serum of Pakistani type 2 diabetes mellitus (T2DM) patients. METHODS: It was a cross-sectional case-control study that included 212 subjects. Subjects without diabetes were labeled as Group-I (30 healthy volunteers), Group-II (30 T2DM without retinopathy), and Group-III (152 T2DM with retinopathy). The serum level of IL-17 was determined by ELISA technique. Data was analysed using SPSS 17.0 and one way ANOVA to observe group mean differences. RESULTS: More females were in Group-II (83%) and Group-III (66%) compared to Group-I (30%). The age of subjects was higher in Group-III (50 years) and Group-II (49 years) compared to Group-I (34 years). Group-III had longer mean duration of disease (10.51 years) than Group-II (7.76 years). Group-I had increased levels of IL-17 followed by Group-II and Group-III. On comparison, statistically significant differences were observed among the three groups, and between Group-I and Group-III, but there was no significant difference between Group-I and Group-II, nor between Group-II and Group-III. Further, on comparison of age, gender, and duration of disease there were significant differences while there was no significant difference between the percentages of HbA1c. CONCLUSIONS: Age, gender, and duration of diabetes may contribute in the development of T2DM retinopathy while serum level of IL-17 was inversely associated with T2DM and retinopathy.
BACKGROUND:Diabetes mellitus (DM) is a health concern because it leads to complications such as retinopathy. Pakistan has 6.9 million DM affected people that will double by 2025. A study was designed to determine the level of IL-17 in the serum of Pakistani type 2 diabetes mellitus (T2DM) patients. METHODS: It was a cross-sectional case-control study that included 212 subjects. Subjects without diabetes were labeled as Group-I (30 healthy volunteers), Group-II (30 T2DM without retinopathy), and Group-III (152 T2DM with retinopathy). The serum level of IL-17 was determined by ELISA technique. Data was analysed using SPSS 17.0 and one way ANOVA to observe group mean differences. RESULTS: More females were in Group-II (83%) and Group-III (66%) compared to Group-I (30%). The age of subjects was higher in Group-III (50 years) and Group-II (49 years) compared to Group-I (34 years). Group-III had longer mean duration of disease (10.51 years) than Group-II (7.76 years). Group-I had increased levels of IL-17 followed by Group-II and Group-III. On comparison, statistically significant differences were observed among the three groups, and between Group-I and Group-III, but there was no significant difference between Group-I and Group-II, nor between Group-II and Group-III. Further, on comparison of age, gender, and duration of disease there were significant differences while there was no significant difference between the percentages of HbA1c. CONCLUSIONS: Age, gender, and duration of diabetes may contribute in the development of T2DM retinopathy while serum level of IL-17 was inversely associated with T2DM and retinopathy.
Authors: Ekta Lachmandas; Corina N A M van den Heuvel; Michelle S M A Damen; Maartje C P Cleophas; Mihai G Netea; Reinout van Crevel Journal: J Diabetes Res Date: 2015-12-29 Impact factor: 4.011
Authors: Jonathan Uriel Quevedo-Martínez; Yonathan Garfias; Joanna Jimenez; Osvaldo Garcia; Diana Venegas; Victor Manuel Bautista de Lucio Journal: BMJ Open Ophthalmol Date: 2021-06-30